The Annual General Meeting of Tripep AB was held in Stockholm on 1 April, 2009.
Annual Report and discharge from liability
The company's Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer were discharged from liability for the financial year 2008.
Election of Board of Directors and Chairman of the Board and compensation to the Board
Thomas Lynch, Anders Vahlne and Matti Sällberg were appointed to the Board of Directors, (all re-elected).
Thomas Lynch was re-elected as Chairman of the Board.
The Meeting resolved that no directors' fees shall be payable.
Authorisation to issue shares, convertibles debentures and warrants
The Meeting authorized the Board of Directors to resolve, at one or more occasions until the next Annual General Meeting, to issue new shares, convertible debentures and/or warrants with consideration in cash or in kind or by set-off or otherwise with conditions and thereby be able to resolve to disapply the share¬holders pre-emption rights.
Reduction of the share capital and new articles of association
The meeting resolved to reduce the share capital for covering of losses and to adopt new articles of association which reflects the lower share capital.
For more information, please contact:
Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website:
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.